Leber Congenital Amaurosis 10
6 clinical trials · Condition
◉ Watch Leber Congenital Amaurosis 10
| Record | Firm | Date |
|---|---|---|
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. (NCT04855045) | ProQR Therapeutics | 2021-03-23 |
| Single Ascending Dose Study in Participants With LCA10 (NCT03872479) | Editas Medicine, Inc. | 2019-09-26 |
| Extension Study to Study PQ-110-001 (NCT03140969) (NCT03913130) | Laboratoires Thea | 2019-05-13 |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) (NCT03913143) | ProQR Therapeutics | 2019-04-04 |
| Natural History Study of CEP290-Related Retinal Degeneration (NCT03396042) | Editas Medicine, Inc. | 2017-12-17 |
Track Leber Congenital Amaurosis 10 automatically
Every clearance here is in the API, with alerts when new ones post.